David Schenkein
Overview
Explore the profile of David Schenkein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
2095
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Geoerger B, Schiff M, Penard-Lacronique V, Darin N, Saad S, Duchon C, et al.
Nat Med
. 2023 May;
29(6):1358-1363.
PMID: 37248298
D-2-hydroxyglutaric aciduria type II (D2HGA2) is a severe inborn disorder of metabolism caused by heterozygous R140 mutations in the IDH2 (isocitrate dehydrogenase 2) gene. Here we report the results of...
2.
Levin J, Holtzman S, Maraganore J, Hastings P, Cohen R, Dahiyat B, et al.
Nat Biotechnol
. 2017 Mar;
35(3):204-206.
PMID: 28267733
No abstract available.
3.
Pollyea D, Kohrt H, Zhang B, Zehnder J, Schenkein D, Fantin V, et al.
Leuk Lymphoma
. 2012 Jun;
54(2):408-10.
PMID: 22680765
No abstract available.
4.
Attar E, De Angelo D, Supko J, Damato F, Zahrieh D, Sirulnik A, et al.
Clin Cancer Res
. 2008 Mar;
14(5):1446-54.
PMID: 18316568
Purpose: Proteasome inhibition results in cytotoxicity to the leukemia stem cell in vitro. We conducted this phase I study to determine if the proteasome inhibitor bortezomib could be safely added...
5.
Richardson P, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, et al.
Blood
. 2007 Aug;
110(10):3557-60.
PMID: 17690257
Initial analysis of the Assessment of Proteasome Inhibition for Extending Remissions (APEX) trial of relapsed multiple myeloma patients showed significantly longer time to progression, higher response rate, and improved survival...
6.
Lara Jr P, Koczywas M, Quinn D, Lenz H, Davies A, Lau D, et al.
J Thorac Oncol
. 2007 Apr;
1(2):126-34.
PMID: 17409841
Background: This phase I study was performed to determine the dose-limiting toxicity and maximum tolerated dose (MTD) of docetaxel in combination with bortezomib in patients with advanced non-small cell lung...
7.
Strauss S, Higginbottom K, Juliger S, Maharaj L, Allen P, Schenkein D, et al.
Cancer Res
. 2007 Mar;
67(6):2783-90.
PMID: 17363600
Bortezomib is a proteasome inhibitor with proven efficacy in multiple myeloma and non-Hodgkin's lymphoma. This study reports the effects of bortezomib in B-cell lymphoma cell lines with differing sensitivity to...
8.
Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng W, Roels S, et al.
Blood
. 2006 Dec;
109(8):3177-88.
PMID: 17185464
The aims of this study were to assess the feasibility of prospective pharmacogenomics research in multicenter international clinical trials of bortezomib in multiple myeloma and to develop predictive classifiers of...
9.
Hideshima T, Neri P, Tassone P, Yasui H, Ishitsuka K, Raje N, et al.
Clin Cancer Res
. 2006 Oct;
12(19):5887-94.
PMID: 17020997
Purpose: The purpose of this study is to delineate the biological significance of IkappaB kinase (IKK) beta inhibition in multiple myeloma cells in the context of bone marrow stromal cells...
10.
Gerecitano J, Goy A, Wright J, MacGregor-Cortelli B, Neylon E, Gonen M, et al.
Br J Haematol
. 2006 Aug;
134(4):391-8.
PMID: 16882131
Bortezomib is the first proteasome inhibitor to be approved for use in haematological malignancies. Although a rash has been described as a common adverse event associated with the drug, it...